The era of active surveillance for low-risk prostate cancer is here.

• Petros Sountoulides ^[1] ; Can Obek ^[2]
  1. [1] General Hospital of Veria, Grecia
  2. [2] Acibadem Healthcare Group, Turquía
• Localización: Archivos españoles de urología, ISSN 0004-0614, Tomo 69, Nº. 2 (Marzo 2016), 2016, págs. 49-51
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Prostate cancer is the most commonly diagnosed malignancy in men as 1 out of 6 men are at risk for being diagnosed with this disease during their lifetime. The observed increase in the prevalence of prostate cancer has been mainly attributed to the widespread use of prostate specific antigen (PSA) testing for opportunistic screening (1). Screen-detected prostate cancer cases nowadays account for approximately 50% of newly diagnosed cases; moreover most of these patients are diagnosed with favorable risk CaP; (i.e. T1c-T2a, Gleason Score≤6, PSA<10).

    The diagnosis of screen-detected, low risk, prostate cancer that potentially would have never become clinically significant during the individual’s lifetime constitutes “overdiagnosis”. Although overdiagnosis is difficult to define and quantify, estimates of overdiagnosis vary widely (from 1.7 to 46%) depending on many parameters such as population, method of screening and method of calculation (2).